Acquired resistance to erlotinib in EGFR mutation-positive lung adenocarcinoma among Hispanics (CLICaP)

Vista sencilla de ítem
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorArrieta, Oscar
dc.contributor.authorZapata, Martín Ignacio
dc.contributor.authorRojas Puentes, Leonardo
dc.contributor.authorWills, Beatriz
dc.contributor.authorReguart, Noemí
dc.contributor.authorKarachaliou, Niki
dc.contributor.authorCarranza Isaza, Hernán
dc.contributor.authorVargas Báez, Carlos Alberto
dc.contributor.authorOtero, Jorge
dc.contributor.authorArchila, Pilar
dc.contributor.authorMartín, Claudio
dc.contributor.authorCorrales, Luis
dc.contributor.authorCuello, Mauricio
dc.contributor.authorOrtiz, Carlos
dc.contributor.authorPino, Luis E.
dc.contributor.authorRosell, Rafael
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.contributor.orcidCarranza Isaza, Hernán [0000-0002-3593-7405]
dc.contributor.orcidVargas Báez, Carlos Alberto [0000-0002-6076-8260]
dc.contributor.orcidRojas Puentes, Leonardo [0000-0002-7865-5424]
dc.date.accessioned2020-11-04T20:27:02Z
dc.date.available2020-11-04T20:27:02Z
dc.date.issued2017
dc.description.abstractenglishLung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations. The purpose of this study was to assess histological and clinical characteristics and survival outcomes in Hispanic EGFR mutated lung cancer patients after disease progression. Patients and methods: EGFR mutation-positive lung cancer patients (n = 34) with acquired resistance to the EGFR-TKI erlotinib were identified from 2011 to 2015. Post-progression tumor specimens were collected for molecular analysis. Post-progression interventions, response to treatment, and survival were assessed and compared among all patients and those with and without T790M mutations. Mean age was 59.4 ± 13.9 years, 65% were never-smokers, and 53% had a performance status 0-1. All patients received erlotinib as first-line treatment. Identified mutations included: 60% DelE19 (Del746-750) and 40% L858R. First-line erlotinib overall response rate (ORR) was 61.8% and progression free survival (PFS) was 16.8 months (95% CI: 13.7-19.9). Acquired resistance mutations identified were T790M mutation (47.1%); PI3K mutations (14.7%); EGFR amplification (14.7%); KRAS mutation (5.9%); MET amplification (8.8%); HER2 alterations (5.9%, deletions/insertions in e20); and SCLC transformation (2.9%). Of patients, 79.4% received treatment after progression. ORR for post-erlotinib treatment was 47.1% (CR 2/PR 14) and median PFS was 8.3 months (95% CI: 2.2-36.6). Median overall survival (OS) from treatment initiation was 32.9 months (95% CI: 30.4-35.3), and only the use of post-progression therapy affected OS in a multivariate analysis (p = 0.05). Hispanic patients with acquired resistance to erlotinib continued to be sensitive to other treatments after progression. The proportion of T790M+ patients appears to be similar to that previously reported in Caucasians.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1007/s11523-017-0497-2
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1776-260X
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/4626
dc.language.isoeng
dc.publisherSpringer Linkspa
dc.publisher.journalTargeted Oncologyspa
dc.relation.ispartofseriesTargeted Oncology, 1776-260X, Vol. 12, No. 4, 2017, p. 513-523spa
dc.relation.urihttps://link.springer.com/article/10.1007/s11523-017-0497-2
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2017
dc.rights.localAcceso abiertospa
dc.subject.decsClorhidrato de erlotinibspa
dc.subject.decsAdenocarcinoma del pulmónspa
dc.subject.decsGenes erbB-1spa
dc.titleAcquired resistance to erlotinib in EGFR mutation-positive lung adenocarcinoma among Hispanics (CLICaP)spa
dc.title.translatedAcquired resistance to erlotinib in EGFR mutation-positive lung adenocarcinoma among Hispanics (CLICaP)spa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos